Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- 9.53 --
11/04/2022* 08:30 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 9.77 8.87 10.12%
08/03/2022 08:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 11.49 9.80 17.28%
05/04/2022 08:30 EST Earnings Call Q1 2022 -- -- --
02/04/2022 -- Results Q4 2021 23.72 20.30 16.85%
02/04/2022 08:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since 20.76%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
URL https://www.regeneron.com
Investor Relations URL https://investor.regeneron.com/
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Blend
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
16.41%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.90%
--
--
--
--
28.09%
434.1%
143.1%
-52.36%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
17.66%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
17.11%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-23.49%
As of October 03, 2022.

Profile

Edit
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
URL https://www.regeneron.com
Investor Relations URL https://investor.regeneron.com/
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Blend
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IBB 551.33M USD 7.29%
COWZ 180.62M USD 2.59%
FTCS 179.07M USD 2.37%
AULNX 354.09M USD 2.35%
VGHCX 906.41M USD 2.00%
JLGZX 585.41M USD 1.66%
XLV 600.90M USD 1.62%
FCNKX 1.422B USD 1.36%
USMV 349.04M USD 1.29%
VHT 213.13M USD 1.15%
CGFFX 1.546B USD 0.77%
CNPFX 797.02M USD 0.75%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter REGN Tweets